A $2.1 million grant from the National Institutes of Health will allow University of Arizona Health Sciences researchers to study the links between knee structure changes and clinical outcomes in people with osteoarthritis.
If you are not happy with the results below please do another search
50 search results for:
This whitepaper covers the role that the BMC Helix portfolio can play in helping healthcare organizations to modernize their infrastructure and drive digital transformation.
Kate Rawson, one of the most insightful and practical observers of the health policy scene in Washington, offers the Coalition for Healthcare Communication her well-informed analysis and a Q&A format.
On the strength of data from Alzamend Neuro’s Phase I study of its lead compound AL001 being developed for the treatment of Alzheimer’s disease, the company is looking to commence a Phase II multiple ascending dose study for that indication during the second quarter of 2022.
The World Health Organization (WHO) is looking into allegations a regional director in Asia bullied staff, used racist language and leaked sensitive vaccine data to Japan, accusations the official denies.
The world’s first medical trial authorized to deliberately expose participants to the coronavirus is seeking more volunteers as it steps up efforts to help develop better vaccines.
While the Centers for Medicare & Medicaid Services undergoes the comment period on its national coverage decision for Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab), Biogen and its partner company Eisai released additional details about the Phase IV post-marketing study of the drug.
Ogilvy Health’s new chief creative officer Adam Hessel talks about why he crossed over into healthcare from the consumer sector, what he brings to Ogilvy Health, and where he wants to see the healthcare industry go in general when it comes to creativity.
Fingerpaint’s Bill McEllen talked to Med Ad News about his new role as global president and the company’s plans moving forward.
Peregrine Market Access, a leading life science commercialization partner, was selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria. The breakthrough bladder cancer diagnostic test Oncuria is being developed to aid in detection, therapy choice, and disease monitoring. Under a multiyear, multimillion dollar agreement, Peregrine Market Access will lead the U.S. launch of Oncuria.
Charles Joel Rosser
“After an extensive search for the right commer